Skip to main content
SpringerLink
Log in

The UK NICE has issued a final appraisal determination that the NHS should not provide lapatinib [Tyverb]

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. NICE closes door to GSK's breast cancer drug Tyverb, Sutent in question. Pharma Times: Online first [2 pages], 5 Mar 2009. Available from: URL: http://www.pharmatimes.com.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The UK NICE has issued a final appraisal determination that the NHS should not provide lapatinib [Tyverb]. Pharmacoecon. Outcomes News 574, 3 (2009). https://doi.org/10.2165/00151234-200905740-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905740-00005

Keywords

Search

Navigation